Market Place
Sourcing Support
Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process
27 Mar 2023 //
GLOBENEWSWIRE
Codiak Biosciences files for bankruptcy
27 Mar 2023 //
FIERCE BIOTECH
ATUM Announces Agreement with Codiak to Support Manufacturing of Therapeutics
24 Jan 2023 //
BUSINESSWIRE
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
28 Nov 2022 //
GLOBENEWSWIRE
Codiak BioSciences Reports 3Q FYR and Operational Progress
03 Nov 2022 //
GLOBENEWSWIRE
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine
12 Oct 2022 //
GLOBENEWSWIRE
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity
05 Oct 2022 //
GLOBENEWSWIRE
Codiak Announces Proposed Public Offering of Common Stock and Warrants
12 Sep 2022 //
GLOBENEWSWIRE
Codiak Announces Pricing of $20 M Public Offering of Common Stock and Warrants
12 Sep 2022 //
GLOBENEWSWIRE
Codiak BioSciences Announces Program Reprioritization and Corporate
30 Aug 2022 //
GLOBENEWSWIRE
Codiak`s $2.5M check in July isn’t enough to stave off job cuts & restructuring
30 Aug 2022 //
FIERCEBIOTECH
Codiak BioSciences Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush Conferences
03 Aug 2022 //
GLOBENEWSWIRE
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
11 Jul 2022 //
GLOBENEWSWIRE
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
05 Jul 2022 //
GLOBENEWSWIRE
Codiak Provides Platform-Validating Clinical Update and Data from PI Trials
30 Jun 2022 //
GLOBENEWSWIRE
Codiak Initiates Dosing in PI Trial of exoASO-STAT6 with Advanced Cancers
29 Jun 2022 //
GLOBENEWSWIRE
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy
17 May 2022 //
GLOBENEWSWIRE
Codiak BioSciences Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
02 May 2022 //
GLOBENEWSWIRE
Codiak Presents New Preclinical Data on Pan Beta-Coronavirus Vaccine
20 Apr 2022 //
GLOBENEWSWIRE
Codiak Demonstrates Significant Systemic Anti-Tumor Activity
08 Apr 2022 //
GLOBENEWSWIRE
Codiak BioSciences Reports Q4 and Full Year 2021 Financial Results
10 Mar 2022 //
PRESS RELEASE
Data from Codiak’s exoASO-STAT6 Preclinical Development Program
18 Feb 2022 //
GLOBENEWSWIRE
Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2
02 Dec 2021 //
GLOBENEWSWIRE
Lonza enters the exosome therapy space with acquisition of still-new Codiak site
05 Nov 2021 //
ENDPTS
Lonza Acquires Exosome Manufacturing Facility from Codiak BioSciences
02 Nov 2021 //
CONTRACTPHARMA
Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic
01 Oct 2021 //
GLOBENEWSWIRE
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
18 Aug 2021 //
GLOBENEWSWIRE
Codiak BioSciences Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Codiak BioSciences to Present at the Virtual William Blair Biotech Conference
07 Jul 2021 //
GLOBENEWSWIRE
Codiak BioSciences Announces B. Sorensen to Scientific Advisory Board Member
06 Jul 2021 //
GLOBENEWSWIRE
Codiak BioSciences Expands Executive Leadership
15 Jun 2021 //
GLOBENEWSWIRE
New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes
11 May 2021 //
GLOBENEWSWIRE
Codiak to Present Preclinical Data Demonstrating Broad Potential Applications
27 Apr 2021 //
GLOBENEWSWIRE
Data from Codiak’s exoSTING™ Preclinical Development Program for Solid Tumors
22 Apr 2021 //
GLOBENEWSWIRE
Codiak to Present Data from Two Novel Engineered Exosome Therapeutic
10 Mar 2021 //
GLOBENEWSWIRE
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™
04 Feb 2021 //
GLOBENEWSWIRE
Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published
21 Jan 2021 //
GLOBENEWSWIRE
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating
30 Dec 2020 //
GLOBENEWSWIRE
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™
09 Nov 2020 //
GLOBENEWSWIRE
Codiak lands on Wall Street in second shot at IPO, raises $83M
15 Oct 2020 //
ENDPTS
Codiak Announces Pricing of Initial Public Offering - Oct 14, 2020
13 Oct 2020 //
BIOSPACE
Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™
01 Oct 2020 //
BUSINESSWIRE
Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™
01 Oct 2020 //
PIPELINEREVIEW
Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12
15 Sep 2020 //
PRESS RELEASE
Codiak files for an IPO, again, this time shooting for a nine-digit raise
10 Sep 2020 //
ENDPTS
Codiak Biosciences readies $100M IPO
09 Sep 2020 //
SEEKINGALPHA
Sarepta wagers $72.5 on neuromuscular disease collaboration
24 Jun 2020 //
THEPHARMALETTER
Sarepta and Codiak BioSciences to develop rare disease therapies
23 Jun 2020 //
PHARMACEUTICAL-TECHNOLOGY
Codiak to Present New Preclinical Data on exoASO™-STAT6 and exoASO-C/EBP?
15 Jun 2020 //
BUSINESSWIRE
Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™
01 Jun 2020 //
BUSINESSWIRE
Codiak Presents New Preclinical Data Potential of EngEx™ Engineered Exosomes
15 May 2020 //
BUSINESSWIRE
Codiak to Present Preclinical Data at the American Society Gene & Cell Therapy
30 Apr 2020 //
BUSINESSWIRE
